TLDR Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
Three years ago, a randomized, double-blinded, placebo-controlled trial involving 236 subjects with mild to moderate COVID-19 found that Proxalutamide, an androgen receptor antagonist, significantly accelerated viral clearance and reduced time to clinical remission. On Day 7, 82% of the subjects in the Proxalutamide group had non-detectable SARS-CoV-2 compared to 31% in the placebo group. The average clinical remission time for patients treated with Proxalutamide was 4.2 ±5.4 days, compared to 21.8 ±13.0 days in the placebo group. The drug's efficacy may be due to its ability to suppress membrane-attached ACE2, blocking SARS-CoV-2 cell entry, among other potential mechanisms.
Cited in this study
7 / 7 results
36 citations
,
April 2021 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
32 citations
,
December 2020 in “Journal of The American Academy of Dermatology” AGA linked to worse COVID-19 outcomes in men.
29 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” Women with high androgen levels may have more severe COVID-19 symptoms.
26 citations
,
October 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
119 citations
,
August 2020 in “Journal of The American Academy of Dermatology” Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
134 citations
,
July 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.